Sorrento Therapeutics (SRNE) Reports Q3 Loss of $0.03/Share

Sorrento Therapeutics (NASDAQ: SRNE) reported Q3 EPS of ($0.03), versus ($0.27) reported last year. Revenue for the quarter came in at $1.1 million, versus $1.28 million reported last year.

For earnings history and earnings-related data on Sorrento Therapeutics (SRNE) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lululemon (LULU) PT Lowered to $115 at Freedom Broker
• SoundHound AI completes LivePerson acquisition, names new CFO